The shares of Enservco Corporation (NYSE:ENSV) has been pegged with a rating of Outperform by Northland Capital in its latest research note that was published on November 13, 2015. The Basic Materials company has also assigned a $1.25 price target. Northland Capital wasn’t the only research firm that published a report of Enservco Corporation, with other equities research analysts also giving their opinion on the stock. Northland Capital advised investors in its research note published on March 19, 2015, to Outperform the ENSV stock while also putting a $2.75 price target. The stock had earned Outperform rating from Northland Capital Markets when it published its report on September 08, 2014. That day the Northland Capital set price target on the stock to $4.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 1 advised investors to purchase the stock. The consensus currently stands at a Buy while its average price target is $0.50. The price of the stock the last time has raised by 45.00% from its 52-Week high price while it is -75.83% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 43.25.
The shares of the company added by 9.78% during the trading session on Tuesday, reaching a low of $0.15 while ending the day at $0.17. During the trading session, a total of 1.58 million shares were traded which represents a -340.68% decline from the average session volume which is 359590.0 shares. ENSV had ended its last session trading at $0.16. Enservco Corporation debt-to-equity ratio currently stands at 53.83, while its quick ratio hovers at 0.90 ENSV 52-week low price stands at $0.12 while its 52-week high price is $0.72.
In the second quarter last year, the firm recorded $0.00 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -50.0%.
Investment analysts at H.C. Wainwright published a research note on January 13, 2020 where it informed investors and clients that Microbot Medical Inc. (NASDAQ:MBOT) is now rated as Buy. Their price target on the stock stands at $26. H.C. Wainwright also rated MBOT as Reiterated on December 24, 2019, with its price target of $12 suggesting that MBOT could surge by 3.42% from its current share price. Even though the stock has been trading at $12.48/share, analysts expect it to down by -7.13% to reach $12.00/share. It started the day trading at $12.80 and traded between $11.50 and $11.59 throughout the trading session.
A look at its technical shows that MBOT’s 50-day SMA is 7.21 while its 200-day SMA stands at 6.36. The stock has a high of $20.15 for the year while the low is $4.06. The stock, however, witnessed a rise in its short on 12/31/19. Compared to previous close which recorded 142444.52 shorted shares, the short percentage went higher by 202.35%, as 430,681 ENSV shares were shorted. At the moment, only 2.35% of Microbot Medical Inc. shares were sold short. The company’s average trading volume currently stands at 1.15M shares, which means that the short-interest ratio is just 0.12 days. Over the past seven days, the company moved, with its shift of 0.26%. Looking further, the stock has raised 122.88% over the past 90 days while it gained 119.51% over the last six months.
The change in the stock’s fortunes has led to several institutional investors altering their holdings of the stock. The Renaissance Technologies LLC sold more MBOT shares, decreasing its portfolio by -2.58% during the last quarter. This move now sees The Renaissance Technologies LLC selling -5,338 shares in the last quarter, thus it now holds 201,549 shares of MBOT, with a total valuation of $2,049,753. BlackRock Fund Advisors meanwhile sold more MBOT shares in the recently filed quarter, changing its stake to $1,853,106 worth of shares.
Similarly, Sabby Capital LLC decreased its Microbot Medical Inc. shares by 0.00% during the recently filed quarter. After selling 83,333 shares in the last quarter, the firm now controls 0 shares of Microbot Medical Inc. which are valued at $847,497. Following these latest developments, around 10.42% of Microbot Medical Inc. stocks are owned by institutional investors and hedge funds.